US PTAB Patent Cases
8,722 decisions indexed
Page 85 of 291 · 8,722 total
Mercedes-Benz Group AG et al. v.Phelan Group, LLC
Mercedes‑Benz and Phelan Group settled their IPR dispute over U.S. Patent 10,259,465 B2. The Board granted a joint motion to terminate the proceeding and treated the settlement agreement as confidential business information.
Mercedes-Benz Group AG et al. v.Phelan Group, LLC
Mercedes‑Benz and The Phelan Group jointly filed a motion to keep their settlement agreement confidential under 35 U.S.C. § 317(b) and to terminate the ongoing IPR. The Board is asked to seal the agreement from public disclosure.
Mercedes-Benz Group AG et al. v.Phelan Group, LLC
Mercedes-Benz and Phelan Group filed a joint motion to terminate IPR2025-00919 after reaching a settlement that resolves all disputes over Patent No. 10,259,465.
Mercedes-Benz Group AG et al. v.Phelan Group, LLC
Mercedes‑Benz has filed an IPR petition challenging all 20 claims of the Phelan Group’s driver‑authentication patent, asserting anticipation and obviousness over Murphy, Arshad, Adams, Wu and Petrik references.
Meta Platforms, Inc. v.Resonant Systems, Inc.
Meta Platforms petitions the PTAB to invalidate claims 2 and 3 of Resonant’s ’337 haptic‑feedback patent, arguing obviousness over multiple prior‑art references and seeking to join Apple’s parallel IPR.
Mercedes-Benz Group AG et al. v.Phelan Group, LLC
Mercedes-Benz Group AG successfully petitioned to institute IPR against Phelan Group's driver safety patent (10,259,465), challenging all 20 claims based on obviousness and anticipation using the 'Murphy' prior art.
Kangxi Communications Technologies v.Skyworks Solutions Canada, Inc. et al.
Kangxi Communications challenges the USPTO’s discretionary denial of institution for its IPR against Skyworks’ 7,409,200 RF transceiver patent, arguing the agency’s new “settled expectations” doctrine is unlawful. The petition seeks Director Review to vacate the denial and have the case instituted on the merits.
Sun Pharmaceutical Industries, Inc. v.Nivagen Pharmaceuticals, Inc.
Nivagen successfully opposes Sun Pharmaceutical’s request for a Director review of the institution denial, arguing that Sun raised new issues and failed to meet the rehearing standard. The Board affirms the Acting Director’s discretionary denial under 35 U.S.C. § 314(a).
Samsung Electronics Co., Ltd. et al. v.Hermes IP Management LLC
Samsung Electronics and Hermes IP Management settled their IPR dispute over U.S. Patent 8,855,720 before the Board instituted a trial. The settlement agreement was treated as confidential business information.
Sun Pharmaceutical Industries, Inc. v.Nivagen Pharmaceuticals, Inc.
Sun Pharmaceutical has filed a request for Director Review after the PTAB denied institution of its IPR challenging Nivagen’s orphan‑drug patent. The petitioner argues the denial improperly treated claim‑construction issues as discretionary and was issued by the wrong official.
Sun Pharmaceutical Industries, Inc. v.Nivagen Pharmaceuticals, Inc.
The USPTO denied Sun Pharmaceutical's request for Director Review of the institution denial in IPR2025-00893, leaving the original decision that the IPR would not be instituted unchanged.
Samsung Electronics Co., Ltd. et al. v.Hermes IP Management LLC
Samsung Electronics and Hermes IP Management have settled their IPR dispute over U.S. Patent 8,855,720 and jointly moved to terminate the proceeding, requesting the settlement be kept confidential under statutory authority.
Samsung Electronics Co., Ltd. et al. v.Hermes IP Management LLC
Samsung and Hermes IP reached a settlement and jointly moved to terminate the inter partes review of U.S. Patent 8,855,720 covering a mobile device user interface.
Sun Pharmaceutical Industries, Inc. v.Nivagen Pharmaceuticals, Inc.
Sun Pharmaceutical filed a Director Review request in IPR2025-00893 concerning patent 11878076 owned by Nivagen Pharmaceuticals. The Patent Owner may file a limited response within five business days, and no new evidence is allowed.
Sun Pharmaceutical Industries, Inc. v.Nivagen Pharmaceuticals, Inc.
Sun Pharmaceutical Industries petitions the PTAB to invalidate claims 1‑20 of Nivagen’s ’076 patent covering lyophilized phenobarbital sodium formulations. The petition alleges obviousness over PIF, Parker, and West‑Ward references and anticipation/obviousness by the ’608 Publication, and challenges the patent’s priority date and written description support.
Kangxi Communications Technologies v.Skyworks Solutions Canada, Inc. et al.
Kangxi Communications has filed an IPR petition against Skyworks’ 7,409,200 patent covering multi‑die RF front‑end modules. The challenger alleges obviousness over Garlepp and over a Magoon‑Ngompe combination. The petition seeks institution of the IPR and cancellation of the claims.
Samsung Electronics Co., Ltd. et al. v.Hermes IP Management LLC
Samsung has filed an IPR petition challenging all 16 claims of Hermes’s ’720 patent covering idle‑screen management on mobile devices, asserting obviousness over Hawkins, Majava and Nielsen.
Milwaukee Electric Tool Corporation v.Klein Tools, Inc.
Milwaukee Electric Tool Corp. petitions the PTAB to invalidate Klein Tools' luminescent fish tape patent, asserting obviousness, lack of written description, and indefiniteness across all 18 claims.
Samsung Electronics Co. Ltd. et al. v.VB Assets, LLC
Samsung has filed an IPR petition challenging VB Assets' U.S. Patent 8,886,536, which covers voice‑based advertising. The petition alleges that 55 claims are obvious over a combination of prior‑art references, invoking 35 U.S.C. §103. The Board has yet to rule.
Milwaukee Electric Tool Corporation v.Klein Tools, Inc.
Milwaukee Electric Tool Corp. petitions the PTAB to invalidate Klein Tools' 11,713,209 patent covering luminescent fish tape systems, asserting obviousness over multiple prior‑art references. The petition challenges all 18 claims and seeks cancellation.
Clearwater Paper Corporation v.--
Clearwater Paper has filed a revised IPR petition seeking cancellation of claims 1‑3 and 11 of Graphic Packaging International’s biodegradable paper cup patent, asserting anticipation by Cleveland and obviousness via Nakagawa and Tanner. The petition requests institution of the review.
Clearwater Paper Corporation v.--
Clearwater Paper has filed an IPR petition seeking cancellation of claims 1‑3 and 11 of Graphic Packaging’s biodegradable cup patent, asserting anticipation by Cleveland and obviousness over Nakagawa and Tanner. The petition argues the prior art was not considered during prosecution and requests institution of the trial.
Clearwater Paper Corporation v.--
The PTAB granted institution of IPR for Clearwater Paper Corporation against Graphic Packaging International LLC, challenging claims related to biodegradable paper cups based on prior art references Cleveland and Nakagawa.
ADC Solutions Auto LLC et al. v.The Noco Company
The PTAB granted institution of an inter‑partes review of The Noco Company’s 11,447,023 B2 jump‑starter patent after ADC Solutions Auto demonstrated a reasonable likelihood of success on obviousness grounds. All seven challenged claims will proceed to trial.
ADC Solutions Auto LLC et al. v.The Noco Company
The PTAB instituted an inter partes review of claims 1‑11 of the ’203 battery‑charger patent and granted ADC Solutions Auto LLC’s motion to join the existing Deltran IPR, assigning it an understudy role.
Microsoft Corp. v.VirtaMove, Corp.
Microsoft and VirtaMove jointly filed a motion asking the PTAB to keep their settlement agreement confidential under 35 U.S.C. §317(b). They argue the agreement contains highly sensitive business information that could harm their interests if disclosed.
Microsoft Corp. v.VirtaMove, Corp.
Microsoft and VirtaMove have entered a settlement that resolves all disputes over patent 7,784,058. They jointly moved to terminate the pending inter partes review, citing 35 U.S.C. §317. The Board has not yet ruled on institution, making termination permissible.
Microsoft Corp. v.VirtaMove, Corp.
Microsoft and VirtaMove have settled their dispute over U.S. Patent 7,784,058 and jointly moved to terminate the inter partes review. The Board has not yet decided on institution, making termination permissible under 35 U.S.C. §317.
Microsoft Corp. v.VirtaMove, Corp.
Microsoft and VirtaMove filed a joint motion requesting that their settlement agreement be kept confidential under 35 U.S.C. §317(b). The parties contend the agreement contains highly sensitive business information that should not be disclosed publicly.
Microsoft Corp. v.VirtaMove, Corp.
Microsoft and VirtaMove have settled all disputes over Patent 7,784,058 and jointly moved to terminate the inter partes review. The Board is asked to end the proceeding under 35 U.S.C. § 317.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.